Context Therapeutics Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Context Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2024.
  • Context Therapeutics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 5.3 %, a 62.1% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 5.3 -8.68 -62.1% Sep 30, 2024
Q2 2024 9.3 -2.01 -17.8% Jun 30, 2024
Q1 2024 24.2 +14.8 +156% Mar 31, 2024
Q4 2023 19 +11.6 +155% Dec 31, 2023
Q3 2023 14 +7.21 +107% Sep 30, 2023
Q2 2023 11.3 +0.5 +4.62% Jun 30, 2023
Q1 2023 9.43 Mar 31, 2023
Q4 2022 7.45 Dec 31, 2022
Q3 2022 6.77 Sep 30, 2022
Q2 2022 10.8 Jun 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.